NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $204.26 +1.76 (+0.87%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$201.41▼$204.4050-Day Range$194.35▼$245.2952-Week Range$161.65▼$275.00Volume563,193 shsAverage Volume589,324 shsMarket Capitalization$10.52 billionP/E Ratio24.03Dividend YieldN/APrice Target$231.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Charles River Laboratories International alerts: Email Address Charles River Laboratories International MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside13.1% Upside$231.00 Price TargetShort InterestHealthy3.57% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.45Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth12.37%From $10.99 to $12.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.56 out of 5 starsMedical Sector88th out of 924 stocksCommercial Physical Research Industry3rd out of 12 stocks 3.1 Analyst's Opinion Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 4 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.57% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 1.10%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCharles River Laboratories International has received a 76.18% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Charles River Laboratories International is -0.55. Previous Next 2.5 News and Social Media Coverage News SentimentCharles River Laboratories International has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Charles River Laboratories International this week, compared to 6 articles on an average week.Search Interest7 people have searched for CRL on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows4 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 12.37% in the coming year, from $10.99 to $12.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is 24.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is 24.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.56.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Darwin2024's Must-Watch Stocks!Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] About Charles River Laboratories International Stock (NYSE:CRL)Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Read More CRL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRL Stock News HeadlinesAugust 20 at 2:22 AM | americanbankingnews.comStockNews.com Upgrades Charles River Laboratories International (NYSE:CRL) to "Buy"August 16, 2024 | americanbankingnews.comCharles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Hold" from AnalystsAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 14, 2024 | americanbankingnews.comCharles River Laboratories International (NYSE:CRL) Price Target Cut to $203.00August 14, 2024 | markets.businessinsider.comHold Rating on Charles River Labs Amidst Pharma Restructuring and Uncertain Near-Term EarningsAugust 13, 2024 | globenewswire.comCHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 13, 2024 | americanbankingnews.comCharles River Laboratories International, Inc. (NYSE:CRL) Forecasted to Post Q1 2025 Earnings of $2.53 Per ShareAugust 12, 2024 | americanbankingnews.comCharles River Laboratories International (NYSE:CRL) Price Target Lowered to $210.00 at BarclaysAugust 22, 2024 | Insiders Exposed (Ad)Has Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.August 8, 2024 | benzinga.comCritical Insights From Charles River Analyst Ratings: What You Need To KnowAugust 8, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Charles River Labs (CRL)August 8, 2024 | msn.comCharles River Laboratories International, Inc. (NYSE:CRL) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | bizjournals.comCharles River Labs says it's cutting staff amid ‘headwinds’August 7, 2024 | reuters.comCharles River cuts 2024 forecast as funding crunch among biotech clients persistsAugust 7, 2024 | msn.comCharles River Labs Plummets 17% On 'Bleaker' Expectations For 2024August 7, 2024 | investopedia.comCharles River Labs Says It Expects Sales To Fall, Sending Its Stock TumblingJuly 24, 2024 | finance.yahoo.comCharles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug DiscoveryJuly 16, 2024 | globenewswire.comCRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary DutiesSee More Headlines Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today8/21/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CUSIP15986410 CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees21,400Year Founded1947Price Target and Rating Average Stock Price Target$231.00 High Stock Price Target$290.00 Low Stock Price Target$191.00 Potential Upside/Downside+13.1%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$8.50 Trailing P/E Ratio24.03 Forward P/E Ratio18.59 P/E Growth2.32Net Income$474.62 million Net Margins10.81% Pretax Margin13.36% Return on Equity15.16% Return on Assets6.60% Debt Debt-to-Equity Ratio0.73 Current Ratio1.75 Quick Ratio1.37 Sales & Book Value Annual Sales$4.08 billion Price / Sales2.58 Cash Flow$14.14 per share Price / Cash Flow14.45 Book Value$70.15 per share Price / Book2.91Miscellaneous Outstanding Shares51,510,000Free Float50,840,000Market Cap$10.52 billion OptionableOptionable Beta1.38 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James C. Foster J.D. (Age 73)CEO, President & Chairman Comp: $2.66MMs. Flavia H. Pease (Age 51)Corporate Executive VP & CFO Comp: $1.66MMs. Birgit Girshick (Age 54)Corporate Executive VP & COO Comp: $1.28MMr. Joseph W. LaPlume (Age 50)Corporate Executive Vice President of Corporate Development & Strategy Comp: $928.36kMr. William D. Barbo (Age 63)Corporate Executive Vice President of Community Relations Comp: $1MMr. Michael Gunnar Knell (Age 47)Corporate Senior VP & Chief Accounting Officer Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific OfficerMr. Mark MintzCorporate Senior VP & Chief Information OfficerTodd SpencerCorporate Vice President of Investor RelationsMr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance OfficerMore ExecutivesKey CompetitorsAgilent TechnologiesNYSE:AMettler-Toledo InternationalNYSE:MTDIlluminaNASDAQ:ILMNWatersNYSE:WATBio-TechneNASDAQ:TECHView All CompetitorsInsiders & InstitutionsTruist Financial CorpSold 2,761 shares on 8/21/2024Ownership: 0.072%Northwestern Mutual Wealth Management Co.Bought 6,011 shares on 8/16/2024Ownership: 0.098%Mackenzie Financial CorpSold 2,637 shares on 8/15/2024Ownership: 1.804%APG Asset Management US Inc.Bought 351 shares on 8/15/2024Ownership: 0.029%AlTi Global Inc.Sold 357 shares on 8/15/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $236.40 on January 1st, 2024. Since then, CRL stock has decreased by 13.6% and is now trading at $204.26. View the best growth stocks for 2024 here. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) issued its quarterly earnings data on Wednesday, February, 14th. The medical research company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. The firm's revenue for the quarter was down 7.9% on a year-over-year basis. Read the conference call transcript. Is Charles River Laboratories International buying back stock? Charles River Laboratories International's board initiated a share repurchase plan on Wednesday, August 7th 2024, which permits the company to buy back $1,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its stock is undervalued. What is James C. Foster's approval rating as Charles River Laboratories International's CEO? 291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees. Does Charles River Laboratories International have any subsidiaries? The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and others. Who are Charles River Laboratories International's major shareholders? Charles River Laboratories International's top institutional shareholders include Kayne Anderson Rudnick Investment Management LLC (3.71%), Allspring Global Investments Holdings LLC (2.43%), Earnest Partners LLC (1.95%) and Mackenzie Financial Corp (1.80%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Richard F Wallman. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM) and Abbott Laboratories (ABT). This page (NYSE:CRL) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
